Skip to content
OpenCapital
Get started

SION SION Cash & Equivalents

Cash & Equivalents at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$5.5B+17.5%
AbbVie logo
AbbVieABBV
$9.39B+81.5%
Septerna, Inc. logo
Septerna, Inc.SEPN
$71.61M-65.9%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$173.38M+62.2%
Denali Therapeutics Inc. logo
Denali Therapeutics Inc.DNLI
$390.73M+551%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$274.5M+35.8%

Other financials

Income statement

See full
Operating income-$29.6M-50.6%
Net income-$26.8M-62.5%
EPS (diluted)-$0.60+3.2%

Balance sheet

See full
Total debt$8.4M-11.8%
Total equity$288.2M-18.1%
Total assets$305.0M-17.5%

Cash flow

See full
Operating cash flow-$21.8M-34.1%
CapEx--100%
Free cash flow-$21.8M-33.4%

Valuation

See full
Market cap$1.8B—
Enterprise value$1.74B—

Returns & leverage

See full
Return on equity-26.7%—
Debt / equity0×0.0×
Current ratio22.6×-6.1×

Where this comes from

Reported directly by SION in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: SION’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about SION's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SION's cash & equivalents?
SION (SION) reported cash & equivalents of $64.29M in Q1 2026.
How has SION's cash & equivalents changed year-over-year?
SION's cash & equivalents decreased by 23.2% year-over-year, from $83.66M to $64.29M.
What is the long-term trend for SION's cash & equivalents?
Over 2 years (2023 to 2025), SION's cash & equivalents has grown at a 22.7% compound annual growth rate (CAGR), from $39.48M to $59.41M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.